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In untreated HIV infection, the efficacy of T cell responses decreases over the disease 
course, resulting in disease progression. The reasons for this development are not com-
pletely understood. However, immunosuppressive cells are supposedly crucially involved. 
Treatment strategies to avoid the induction of these cells preserve immune functions and 
are therefore the object of intense research efforts. In this study, we assessed the effect 
of treatment intensification [=5-drug antiretroviral therapy (ART)] on the development of 
suppressive cell subsets. The New Era (NE) study recruited patients with primary HIV 
infection (PHI) or chronically HIV-infected patients with conventional ART (CHI) and applied 
an intensified 5-drug regimen containing maraviroc and raltegravir for several years. We 
compared the frequencies of the immune suppressive cells, namely, the myeloid-derived 
suppressor cells (MDSCs), regulatory B  cells (Bregs), and regulatory T  cells (Tregs), of 
the treatment intensification patients to the control groups, especially to the patients with 
conventional 3-drug ART, and analyzed the Gag/Nef-specific CD8 T cell responses. There 
were no differences between PHI and CHI in the NE population (p >  0.11) for any of 
the studied cell types. Polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC), 
monocytic myeloid-derived suppressor cell (M-MDSC), and the Breg frequencies were 
comparable to those of patients with a 3-drug ART. However, the Treg levels were signifi-
cantly lower in the NE patients than those in 3ART-treated individuals and other control 
groups (p ≤ 0.0033). The Gag/Nef-specific CD8 T cell response was broader (p = 0.0134) 
with a higher magnitude (p = 0.026) in the NE population than that in the patients with 
conventional ART. However, we did not find a correlation between the frequency of 
the immune suppressive cells and the interferon-gamma+ CD8 T  cell response. In the 
treatment intensification subjects, the frequencies of the immune suppressive cells were 
comparable or lower than those of the conventional ART-treated subjects, with surprisingly 
broad HIV-specific CD8 T cell responses, suggesting a preservation of immune function 
with the applied treatment regimen. Interestingly, these effects were seen in both treatment 
intensification subpopulations and were not attributed to the start of treatment in primary 
infection.
Keywords: hiV-1, treatment intensification, immune suppressive cells, myeloid-derived suppressor cells, 
regulatory T cells, regulatory B cells, cD8 T cell response, new era study
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as well, leading to the loss of immune control in chronic viral 
infections.
In HIV infection, the role of Tregs is ambiguous and has not 
been evaluated conclusively (18–25). On the one hand, Tregs were 
found to reduce immune activation, which is a positive effect in 
uncontrolled HIV infection. On the other hand, these cells inhibit 
T cell responses, leading to viral persistence (18, 20, 23).
MDSCs are immature cells with a myeloid origin, which act 
immunosuppressively by inhibiting the functions of T  lympho-
cytes, among others. MDSCs are divided into two major subsets, 
including polymorphonuclear (PMN) and monocytic (M) 
MDSCs (26, 27). In natural HIV infection, PMN-MDSC as well 
as M-MDSC frequencies correlate with the VL and are inversely 
related to the CD4 cell count. ART decreases PMN-MDSC levels 
within 6 weeks (28, 29). However, data on SIV-infected monkeys 
report a minor percentage of M-MDSCs within the complete 
MDSC population and higher levels of PMN-MDSCs during 
ART than that before infection (30).
Recently, studies by Siewe et al. described a direct correlation 
of Breg frequencies and CD8 T cell exhaustion in HIV-infected 
patients (31). Interleukin (IL)-10+ Breg frequencies are signifi-
cantly elevated in viremic patients compared with HIV-uninfected 
individuals (32, 33). However, even ART-treated patients and EC 
still have elevated Breg levels when compared with uninfected 
controls (33).
With the NE study, we had the opportunity to evaluate the 
impact of treatment intensification on the described immuno-
suppressive cells in correlation with HIV-specific CD8 T  cell 
responses. We hypothesized that these patients, especially the 
PHI group, have preserved immune functions and, therefore, 
low levels of Tregs, MDSCs, and Bregs in comparison to patients 
treated with conventional 3-drug ART.
MaTerials anD MeThODs
study subjects
A total of 116 individuals participated in the study after signing 
an informed consent form.
New Era: 24 patients within the scope of an amendment of 
the NE study [EudraCT Number 2008-002070-35, approved by 
the Bayerische Landesärztekammer (BLAEK) and the German 
federal institute for drugs and medical devices (BfARM)] 
and 92 individuals within 4 control groups (study approval by 
the Institutional Review Board of the Ludwig-Maximilians-
Universität, Munich, Germany). The treatment intensifica-
tion within the NE study consisted of two nucleoside reverse 
 transcri ptase inhibitors, a PI, and maraviroc and raltegravir in all 
cases. Patients with a virus with CXCR4 tropism were excluded 
from the study.
Primary HIV infection (=subgroup of NE patients with PHI, 
which was defined by less than two bands in a Western blot analy-
sis; four patients were recruited in Fiebig stage 3 and six patients 
in Fiebig stage 4; n = 10).
Chronic HIV infection (=subgroup of NE patients with CHI; 
the patients were successfully treated with PI-based ART for at 
least 36 months; n = 14).
inTrODUcTiOn
Since 2010, the number of HIV-infected people with access to 
highly active antiretroviral therapy (ART) increased from 7.5 
to 18.2 million in 2016. However, with 36 million people living 
 globally with HIV, only half of them are treated despite intense 
efforts toward access to ART (1). Thus, there is still an urgent need 
for alternative treatment strategies with the aim of either eradicat-
ing the virus or achieving the so-called “functional cure,” mean-
ing a state of complete suppression of the virus in the absence of 
medication and a preservation of the immune response.
Conventional 3-drug ART suppresses viral replication and 
results in an undetectable viral load (VL) in plasma, but an eradi-
cation of the virus has not been achieved so far. Within the New 
Era (NE) study, treatment intensification by adding raltegravir 
and maraviroc to a 3-drug regimen has been investigated with 
the goal of eradication or at least a functional cure. The study 
recruited patients with primary HIV infection (PHI) or patients 
with chronic HIV infection (CHI). PHI was defined by less than 
two bands in a Western blot analysis. CHI patients were already 
treated successfully for at least 36 months with a protease inhibi-
tor (PI) based conventional ART. All the patients had a CD4 nadir 
above 200 cells/μl and no evidence of resistance to the PI-based 
regimen. The aim of the study was to stop residual viremia, as 
well as to reduce and limit the viral reservoir measured by 
proviral DNA (2–4). Before a possible treatment interruption, 
correlates of immune control were assessed in all the patients. 
In earlier studies, a comparable 5-drug ART (also called treat-
ment intensification) was tested with the result that there was no 
differ ence with regard to virus suppression or immune activation 
between the treat ment intensification and conventional ART 
groups (5, 6). However, none of the previous studies evaluated 
the immune suppressive cells in their cohorts. Therefore, in this 
study, we hypothesized that an intensified treatment will have a 
beneficial effect on the development of immune suppressive cells 
in comparison to conventional 3-drug ART.
In early untreated HIV infection, a strong cytotoxic CD8 T lym-
phocyte response (CTL)—among others—effectively decreases 
VL (7–11). However, only <1% of the infected population, 
namely, elite controllers (EC), reaches complete viral suppression 
without ART (12–15). One reason for the viral persistence and 
eventual disease progression is the loss of CTL function over 
the disease course (e.g., production of cytokines/chemokines, 
degranulation) (16, 17). This phenomenon is termed immune 
exhaustion. In addition to immune checkpoints, e.g., PD-1 and 
CTLA-4, immune suppressive cells are said to be responsible 
for immune exhaustion. In HIV infection, well-known immune 
suppressive cells are regulatory T  cells (Tregs). More recently, 
myeloid-derived suppressor cells (MDSCs) and regulatory B cells 
(Bregs) have been described to inhibit T  lymphocyte function 
Abbreviations: 3ART, patients treated with a conventional 3-drug ART; Bregs, 
regulatory B  cells; CHI, chronic HIV infection; CO, controllers; EC, elite 
 controllers; HC, HIV-uninfected controls; M-MDSCs, monocytic myeloid-
derived suppressor cells; NE, New Era; PHI, primary HIV infection; PMN-
MDSCs, polymorphonuclear myeloid-derived suppressor cells; PR, progressors; 
Tregs, regulatory T cells.
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At time of immunological analysis, the median duration 
of intensified treatment (=5 drugs) of all the NE patients was 
5.5  years. Thus, CHI had a median ART duration of 11/9.5–
16.5 years (median/range).
Control groups are defined as follows:
Progressors (PR) (untreated patients in CHI; n = 27): CD4 cell 
count below 400/μl, VL above 10,000 copies/ml.
Controllers (CO) (patients who control HIV infection sponta-
neously in the absence of ART for at least 3 years; n = 21): CD4 
cell count above 500/μl and VL below 2,000 copies/ml (inclu-
ding EC: patients with VL below 40 copies/ml; n = 8).
3ART (patients treated with a conventional 3-drug ART for 
at least 4 years; n = 21): any CD4 cell count and VL below 50 
copies/ml. The median duration of treatment: 10.5/4–18.5 years 
(median/range). One individual in this group was treated with 
maraviroc, but no one was treated with raltegravir. No threshold 
was set for the CD4 count, because this was not done in any of 
the treated groups.
HIV-uninfected controls (HC) (n = 23).
We included two exceptions of those definitions: PR 22 had 
a low CD4 cell count of 80 cells/μl and, therefore, we accepted a 
low-level viremia of 2,100 copies/ml. Whereas CO 13 was an EC 
(infected for 29 years) with a VL below 40 copies/ml and a CD4 
count of 467 cells/μl in the absence of ART.
None of the ART-treated patients experienced treatment failure.
To further interpret our data, we stratified the cohort in the 
following subgroups:
All the patients on any treatment regimen were summarized 
in the subgroup with ART (w ART) and in analogous patients 
untreated in the subgroup without ART (w/o ART).
The clinical characteristics of the study subjects are shown in 
Table 1.
Peripheral Blood Mononuclear  
cell (PBMc) isolation
Peripheral blood mononuclear cells were isolated from freshly 
obtained EDTA blood by Ficoll density gradient centrifuga-
tion (Biocoll Separation Solution, Biochrom, Germany). The 
frequencies of the PMN-MDSCs and M-MDSCs (including 
isotype control) were determined in fresh PBMCs directly 
after blood draw (≤2  h after blood draw). For this reason, 
only individuals living in Munich were included in the MDSC 
studies. The freq uencies of the Bregs and Tregs as well as the 
IL-10 production by the Bregs and the T cell immune responses 
by interferon-gamma enzyme-linked immunospot (Elispot) 
assay were determined using frozen PBMCs from all the study 
subjects.
Flow cytometric analysis
The extracellular staining was performed with fluorescent anti-
bodies using fresh (PMN-MDSCs/M-MDSCs) or frozen (Tregs/
Bregs) PBMCs as previously described (28). The following 
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(Autoimmun Diagnostika GmbH, Strassberg, Germany) and are 
expressed as spot-forming cells (SFC)/106 PBMCs. According 
to Addo et  al., the wells were counted as positive if they had 
at least the total number of the three control values and were 
>50 SFC/106 PBMCs (39). The mean of the control values was 
subtracted of SFC/105. As the upper cutoff limit, 2,000 SFC/106 
PBMCs was chosen. The breadth of the CD8 T cell responses 
was also determined according to Addo et  al. (39): responses 
to two neighboring overlapping peptides were counted as one 
response toward one epitopic region, since some T cell epitopes 
are located in the overlap of the two peptides. In addition, for 
the total magnitude of the CD8 T cell response, we only con-
sidered the higher response of the two neighboring overlapping 
peptides. This conservative approach may potentially underes-
timate the real number or the real magnitude of the CD8 T cell 
responses.
statistical analysis
The statistical analyses were performed using GraphPad Prism 
version 5.0. In most cases, our data were not normally distributed. 
Therefore, we only used non-parametric tests. Comparisons 
between two groups were done with the Mann–Whitney U test, 
and comparisons between more than two groups were first tested 
with the Kruskal–Wallis test. If this was significant (p <  0.05), 
we also did pairwise Mann–Whitney U tests with Bonferroni 
Correction for multiple testing. Four pairwise comparisons were 
considered relevant and were tested for each experiment as fol-
lows: NE vs. 3ART; NE vs. HC; NE vs. PR; and NE vs. CO. The 
corrected level of significance, therefore, was p <  0.0125 when 
HC was included, and it was p < 0.0167 in the experiments with-
out HC. Spearman rank test was used for correlation analyses 
and Wilcoxon signed rank test for paired comparisons (level 
of significance p < 0.05). Only tests with significant results are 
indicated in the figures.
resUlTs
comparable PMn-MDsc Frequencies in 
ne (=Treatment intensification) and 3arT 
Patients
To evaluate the impact of the intensified ART regimen in NE 
patients on the frequencies of PMN-MDSCs, the levels were com-
pared with 3ART patients and to the HC, CO, and PR patients. We 
observed significantly lower PMN-MDSC frequencies in NE vs. 
PR patients (p = 0.002). However, there was no difference to the 
3ART group (p = 0.65) (Figure 1A). The treatment intensification 
subgroups PHI and CHI had comparable PMN-MDSC frequen-
cies (p = 0.97) (Figure 1B). We further stratified all the patients 
with any ART regimen (w ART: NE and 3ART) and patients 
without therapy (w/o ART). Both groups had significantly higher 
percentages of PMN-MDSCs vs. the HC group (w ART vs. HC: 
p = 0.048; w/o ART vs. HC: p = 0.01) (Figure 1C).
Thus, our analysis shows low PMN-MDSC frequencies in 
the treatment intensification-treated individuals, which were, 
however, comparable to the 3ART patients. In addition, all the 
antibodies were used: PMN-MDSCs: CD11b-FITC, CD14-
APC, CD15-PerCP, and CD66b-PE; M-MDSCs: CD11b-FITC, 
CD14-APC, CD33-PE, HLA-DR-PerCP, and PerCP isotype 
control; Bregs: CD19-PerCP, CD24-APC, and CD38-FITC; 
and Tregs: CD4-APC and CD25-FITC (all BioLegend, USA). 
IL-10 production in the Bregs was determined with an intra-
cellular cytokine staining protocol for IL-10-PE (BioLegend). 
The Tregs were stained intracellularly with anti-FoxP3-PE 
(BioLegend) using the FoxP3 staining buffer set (eBiosciences, 
USA) [as described in Ref. (21)]. The cells were analyzed on a 
FACSCalibur (BD, Germany), and the data analysis was done 
using FlowJo software 7.2.1 (TreeStar, Inc., Ashland, OR, USA). 
The gating strategies were according to Vollbrecht et al. (28) and 
Rieber et  al. (34, 35) for PMN-MDSCs. For the gating of the 
M-MDSCs, we used a PerCP isotype control to gate for HLA-DR 
and our gating strategy was according to Dumitru et  al. (36). 
Bregs were gated as CD19+, CD24hi, and CD38hi (31, 33), and the 
Tregs were CD4+, C25+, and FoxP3+. For the gating strategies 
of all the cell types, see Figure S1 in Supplementary Material. 
For the statistics, we indicated the MDSCs, Bregs, and Tregs 
as the percentage of PBMCs in all the subgroups because the 
number of monocytes vary substantially in the subjects with 
chronic viral infections. Each patient was tested once for flow 
cytometric analysis.
Functional analysis of the Bregs
The Bregs show an immunosuppressive function by the pro-
duction of IL-10. For measuring IL-10 production, we stimu-
lated the thawed PBMCs of five PR and five HC in two ways 
[according to Siewe et al. (31, 33)]. First, the cells (106 PBMCs/
ml) were incubated for 48 h with 10 µg/ml CPG-B (oligodeoxy-
nucleotide-2006), 2  µg/ml PAM (palmitoyl-3-cysteine-serine-
lysine-4), and 2 µg/ml CD40L (all InvivoGen, San Diego, CA, 
USA) at 37°C and in 5.0% CO2, and during the last 5  h, the 
cells were supplemented with 1  µg/ml ionomycin, 50  ng/ml 
phorbol-12-myristate-13-acetate (PMA), 50  µg/ml brefeldin 
A (all Sigma), and 1  µl/ml monensin (BD Golgi Stop™ BD 
Biosciences). Second, we only stimulated the cells with ionomy-
cin/PMA. After 2 h of incubation at 37°C/5.0% CO2, brefeldin 
A and monensin were added, and the cells were incubated for 
another 5  h. After the incubation, the cells were washed and 
stained intracellularly for IL-10. The background range was 
<0.02% for IL-10 production.
Peptides
Overlapping synthetic peptides corresponding to the HIV 
 prot eins Gag and Nef were used for screening (15–20 amino 
acids long, overlap of 5–10 amino acids; Gag: HIV-1 SF-2, Nef: 
HIV-1 Bru, NIBSC, England). The peptides had a purity of ≥70%.
interferon-gamma elispot
HIV-specific CD8 T cell responses were quantified by an inter-
feron-gamma Elispot assay using frozen PBMCs (0.5–1 × 105/
well) and peptides (final concentration: 12.5 µg/ml) as described 
previously (37, 38). Interferon-gamma producing cells were 
counted by direct visualization on an AID Elispot Reader 
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FigUre 1 | Frequencies of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). (a) New Era (NE) showed comparable frequencies to 3ART, but 
significantly lower frequencies than progressors (PR) (p = 0.002). (B) Comparable frequencies in the subgroups primary HIV infection (PHI) and chronic HIV infection 
(CHI) (p = 0.97). (c) The PMN-MDSC levels of patients with antiretroviral therapy (w ART) and w/o ART were significantly increased compared with the HIV-
uninfected controls (HC) group (p < 0.048) [HC: n = 10; 3ART: n = 10; NE: n = 19 (PHI: n = 8; CHI: n = 11); PR: n = 10; CO: n = 10].
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ART-treated subjects had PMN-MDSC levels that did not reach 
the level of the HIV-uninfected controls.
comparable M-MDsc Frequencies  
in all the hiV-infected groups
In HIV infection, M-MDSCs are suggested to play a role in T lym-
phocyte suppression (29, 40). Interestingly, in the NE patients, 
the frequencies of the M-MDSCs were significantly higher than 
the PMN-MDSCs (p =  0.008) (Figure  2A), whereas there was 
no significant difference between these cells in the PR patients 
(p =  0.65) (data not shown). In contrast to the PMN-MDSCs, 
the percentages of M-MDSCs in our cohort were significantly 
higher in the treatment intensification patients than those in 
the HC patients (p <  0.0001) but were comparable to those in 
the 3ART patients (p = 0.21) (Figure 2B). Again, within the NE 
groups, the PHI and CHI subgroups showed comparable values 
(p = 0.2) (Figure 2C). In accordance with these data, the analyses 
in patients with or without ART showed comparable frequen-
cies, which were significantly higher than those in the HC group 
(p < 0.002) (Figure 2D).
Taken together, in our study, the M-MDSC levels in treatment 
intensification patients were not different than the 3ART group 
and were significantly higher than the PMN-MDSCs.
low Breg Frequencies in the Treatment 
intensification and the 3arT groups
Since Bregs are a group of immunosuppressive cells only recently 
described in HIV infection, we evaluated them in our cohort 
(31–33). According to Siewe et al., we defined the Bregs as CD19+, 
CD24hi, and CD38hi and showed IL-10 production in these cells 
for a subset of the PR and CO patients. We found significantly 
increased IL-10 production in stimulated vs. unstimulated Bregs 
in all 10 samples tested independent of the stimulation type 
[for ionomycin p =  0.002, for toll-like receptor (TLR) agonists 
p = 0.002; Figure S2 in Supplementary Material]. Overall these 
results showed that, in our assays, phenotypically defined Bregs 
are capable of IL-10 production, and therefore, they are Bregs. As 
previously described, we observed a positive correlation of Breg 
frequencies with VL in viremic HIV-infected patients (rho = 0.46, 
p = 0.009) (Figure 3D).
The NE patients had comparable levels of Bregs compared 
with those of the 3ART patients and the HC group (Figure 3A). 
Their Breg frequencies were significantly lower than those of the 
untreated group of PR patients (p = 0.0004) (Figure 3A). The PHI 
and CHI subgroups showed no difference in Breg frequencies 
among each other (p = 0.46) (Figure 3B). Stratifying the patients 
in the w ART and w/o ART groups revealed that the w ART group 
showed significantly lower frequencies than those of the w/o ART 
group (p =  0.002), and these frequencies were comparable to 
those of the HC group (p = 0.61) (Figure 3C).
In conclusion, Breg levels in the NE patients were not different 
than those of the 3ART patients.
significantly lower relative Treg 
Frequencies in the ne Patients compared 
With 3arT subjects
As a subset of CD4 T  cells, Treg frequencies vary during the 
course of HIV infection, when CD4 T cells diminish with dis-
ease progression. Thus, the differentiation between the relative 
frequencies and the absolute numbers of Tregs is important to 
compare our results to those of other studies. In the NE group, the 
relative Treg levels were highly significantly lower compared with 
those of the 3ART patients (p < 0.0001) (Figure 4A). They were 
also lower than those in the PR and CO groups (p < 0.0001 and 
p = 0.0033, respectively), whereas the difference compared with 
p = 0.008
p = 0.002
p < 0.0001
p < 0.0001
A B C
D
FigUre 2 | Monocytic myeloid-derived suppressor cell (M-MDSC) frequencies. (a) Polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) levels were 
significantly lower than M-MDSCs in the New Era (NE) population (p = 0.008). (B) M-MDSCs in the NE group were similar to the 3ART patients. (c) Comparable 
frequencies in the subgroups primary HIV infection (PHI) and chronic HIV infection (CHI) (p = 0.2). (D) The M-MDSC levels in the patients with antiretroviral therapy 
(w ART) and w/o ART were significantly increased compared with the HIV-uninfected controls (HC) group (p < 0.002) [HC: n = 10; 3ART: n = 10; NE: n = 19 (PHI: 
n = 8; CHI: n = 11); progressors (PR): n = 10; CO: n = 10].
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the HC group failed to reach statistical significance (Figure 4A). 
The PHI and CHI subgroups were again similar (p  =  0.11) 
(Figure 4B). The entity of patients with ART had lower frequen-
cies of relative Tregs than those of the control groups without 
ART (p = 0.002) (Figure 4C).
In absolute cell numbers, the NE subgroups and the total NE 
population had markedly higher Tregs than those of the PR group 
(p = 0.0004, PHI; p = 0.02, CHI; p = 0.0006, NE) (data not shown). 
A higher median CD4 cell count in the PHI subgroup than 
that in CHI (median = 875 cells/μl and median = 676 cells/μl, 
respectively, however, not statistically significant p  =  0.107) 
along with the abovementioned comparable Treg frequencies 
resulted in higher absolute Treg cell counts in the PHI groups 
compared with those in the CHI group, which just missed 
statistical significance (p = 0.08) (Figure 4D). In addition, the 
NE patients showed a significantly strong correlation in the 
absolute numbers of Tregs with the CD4 cell counts (rho = 0.68, 
p = 0.0003) (Figure 4E).
Taken together, the relative Treg levels were significantly 
lower in the NE patients than those in the 3ART patients. For 
this cell type, treatment intensification seems to be advantageous 
compared with conventional ART.
no correlation Between the levels of 
immune suppressive cells and the gag/
nef-specific cD8 T cell response in 
Treatment intensification
Immune suppressive cells inhibit CD8 T  cell responses. 
Therefore, we evaluated if there was a correlation between the 
HIV-specific CD8 T  cell responses and the levels of immune 
suppressive cells studied here for the patients treated with a 
5-drug ART. However, we were not able to demonstrate any 
correlation between the breadth or magnitude of interferon-
gamma+ CD8 T  cells toward Gag and Nef and the inhibitory 
cells, namely, the PMN-MDSCs, M-MDSCs, Bregs, and Tregs 
(data not shown).
A direct association between the levels of inhibitory immune 
cells and the interferon-gamma positive CD8 T cell response was 
not found in the treatment intensification.
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FigUre 3 | Regulatory B cell (Breg) levels and correlation of their frequencies with viral load (VL). (a) There was no difference in the Breg frequencies between the 
New Era (NE) and 3ART patients, but the NE patients showed significantly lower Breg frequencies than progressors (PR) (p = 0.0004). (B) Again, there were 
comparable frequencies in the subgroups primary HIV infection (PHI) and chronic HIV infection (CHI) (p = 0.46). (c) The Breg levels of the patients with antiretroviral 
therapy (w ART) were significantly decreased compared with those w/o ART (p = 0.002) and were similar to the HIV-uninfected controls (HC) group. (D) The Breg 
frequencies directly and significantly correlated with the VL of the viremic HIV-infected patients of our cohort (rho = 0.46, p = 0.009) [HC: n = 16; 3ART: n = 16; NE: 
n = 24 (PHI: n = 10; CHI: n = 14); PR: n = 21; CO: n = 17].
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stronger immune responses Toward gag 
p17 and gag p15 in the ne Patients 
compared With the 3arT Patients
Interestingly, the NE patients revealed a higher number of 
CD8 T  cell responses in Gag and Nef than that of the 3ART 
patients (p = 0.0134) (Figure 5A). In contrast to the comparable 
frequencies of immunosuppressive cells between the PHI and 
CHI groups, the breadth of the CD8 T cell responses in the PHI 
subgroup (median 2, range 1–6) was significantly lower than 
that in the CHI subgroup (median 7, range 0–17; p =  0.029) 
(Figure  5B), showing that the difference between the NE and 
3ART groups was driven by the CHI subgroup. This difference 
was especially interesting, as both groups—CHI and 3ART—
were chronically HIV infected and had comparable times of 
treatment. In addition, the CD4 counts at blood draw as well as 
the CD4 counts before the start of ART were comparable in both 
groups (p = 0.288 and p = 0.97, respectively). This suggested that 
it was a very special group that was selected for the CHI group 
in the NE study.
The total magnitude of the immune responses toward 
Gag and Nef in the NE patients ranged from 0 to 8,030 
SFC/106 PBMCs (median 700) and was therefore significantly 
higher compared with that of the 3ART patients (p = 0.026) 
(Figure  5C). In contrast to the results in the breadth of the 
responses, the NE subgroups PHI and CHI showed a compara-
ble magnitude of CD8 T cell responses (p = 0.28) (Figure 5D). 
Thus, the fewer responses in the PHI groups generated stronger 
amplitudes.
Looking at the distribution of the CD8 T cell responses within 
the viral proteins, Gag p17 and Gag p15 were more often recog-
nized by the CO group and, interestingly, also by the NE group 
than by the other groups. Studying this finding in detail showed 
that the CHI group recognized the Gag subunits p17 and p15, and 
the PHI group did not. Therefore, the CHI patients were similar 
to the CO patients in this respect. Gag p24 and Nef were the most 
frequently recognized protein subunit within all the groups as 
was to be expected (Figure 5E).
Overall, the CHI subgroup had a higher breadth of CD8 T cell 
responses compared with that of the 3ART patients and was com-
parable to the CO patients but did not lead to a higher magnitude 
of responses than that in the PHI group. There were no significant 
correlations between the CD8 T cell responses and frequencies of 
the immune suppressive cells.
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FigUre 4 | Relative frequencies and absolute cell counts of regulatory T cells (Tregs). (a) The New Era (NE) group showed the significantly lowest Treg frequencies 
compared with all the other HIV-infected groups (p < 0.0033). (B) Comparable frequencies in the subgroups primary HIV infection (PHI) and chronic HIV infection 
(CHI) (p = 0.11). (c) As already shown in the regulatory B cells, the relative Treg levels in the patients with antiretroviral therapy (w ART) were significantly decreased 
compared with those w/o ART (p = 0.002) and were similar to the HIV-uninfected controls (HC) group. (D) There was a trend of a higher absolute Treg number in 
the PHI subgroup than in CHI subgroup (p = 0.08). (e) The absolute Treg cell count in the NE group significantly correlated with the CD4 cell counts (rho = 0.68, 
p = 0.0003) [HC: n = 14; 3ART: n = 15; NE: n = 24 (PHI: n = 10; CHI: n = 14); progressors (PR): n = 18; CO: n = 17].
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DiscUssiOn
The NE study evaluated an intensified antiretroviral treatment 
strategy with the primary goal of the eradication of HIV-1. We 
assessed the impact of this 5-drug treatment on several subsets 
of immune suppressive cells in the NE patients before a pos-
sible treatment interruption. Here, we showed that the levels of 
PMN-MDSCs, M-MDSCs, and Bregs were comparable to those 
of patients treated with a conventional 3-drug ART. However, the 
frequencies of the Tregs were significantly lower than those in the 
3ART patients, indicating an advantage of the 5-drug regimen.
Interestingly, this effect was seen in both the NE subpopula-
tions (PHI and CHI) and was not attributed to an early start of 
ART in primary infection. In addition, the NE population showed 
broader and stronger HIV-specific CD8 T cell responses, mainly 
driven by the CHI subgroup.
Myeloid-derived suppressor cell levels are significantly 
 elev ated in chronic progressive HIV infection. This association is 
shown for both subsets of MDSCs, namely, PMN-MDSCs (28, 41) 
and M-MDSCs (29, 42). In SIV infection, PMN-MDSCs increase 
substantially in acute infection, remain higher than before infec-
tion during antiretroviral treatment and rebound after treatment 
interruption (30). In addition, in human disease, MDSC frequen-
cies decline after the start of ART (28, 29). MDSCs inhibit CD8 
and CD4 T cell functions (proliferation, interferon-gamma pro-
duction) and induce Treg levels (28, 29, 42), thereby contributing 
to the immune exhaustion in late stage disease. In our cohort, 
the intensified treatment regimen led to a near-to-normal level 
of PMN-MDSCs compared with that of the HC subjects, while it 
was significantly lower than in the PR patients, and there was no 
difference compared with that of the patients who were treated 
with a 3-drug ART. As a natural limitation, we do not have 
PMN-MDSC levels of the time before HIV infection and cannot 
therefore comment on this comparison. However, within the NE 
cohort, there are a few patients with elevated PMN-MDSCs to 
a level we usually do not find in healthy individuals. This might 
hint to the fact that, also in human disease, PMN-MDSC frequen-
cies do not return to pre-infection levels, as shown in macaques 
(30)—not even with the start of an intensified treatment regimen 
in the very early phase of the infection.
The results for the M-MDSCs are not as straightforward. In 
our study, there was no difference for these cells in any of the HIV-
infected groups (including PR), and all the HIV-infected patients 
had higher M-MDSC levels than those of the HC group. This is 
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FigUre 5 | (a) Breadth of immune responses in the New Era (NE) and control groups. The NE patients had significantly more CD8 T cell responses in Gag and Nef 
than the 3ART patients (p = 0.0134). (B) The chronic HIV infection (CHI) subgroup showed a significantly higher breadth of immune responses than the primary HIV 
infection (PHI) subgroup (p = 0.029). (c) The magnitude of the NE group was significantly higher than in the 3ART patients (p = 0.026). (D) There was no difference 
between the PHI and CHI subgroups, with regard to the magnitude of the CD8 T cell response (p = 0.28). (e) Gag p17 and Gag p15 were more often recognized by 
the NE (especially CHI) and CO groups than by the progressor (PR) and 3ART groups. Spot-forming cells (SFC)/106 peripheral blood mononuclear cells (PBMCs). 
For the magnitude of the CD8 T cell response, all the individual CD8 T cell responses within Gag and Nef were added for each patient [3ART: n = 10; NE: n = 18 
(PHI: n = 7; CHI: n = 11); PR: n = 10; CO: n = 10].
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in contrast to data published by others (29, 42). One cause for this 
difference might be environmental or genetic reasons, as these 
other studies were conducted in dissimilar circumstances. With 
regard to the data from this study, we cannot postulate a beneficial 
effect of the 5-drug regimen on M-MDSC levels.
Regulatory B  cells were defined just recently as an immune 
inhibitory cell type in HIV infection and were therefore included 
in our analysis. They are best characterized by their capability to 
produce IL-10. Similar to a study by Siewe et al., we defined Bregs 
by phenotype (CD19+CD24hiCD38hi) (31, 33). However, we stud-
ied IL-10 production in a subset of individuals to show that we 
were in fact dealing with Bregs. Liu et al. had a different approach 
and evaluated Breg frequencies solely based on IL-10 production 
(32). In chronic, untreated HIV infection, Breg levels are signifi-
cantly higher than those in HC, correlate directly with VL and 
are inversely related with the CD4 count (31, 32, 43). In addition, 
Bregs inhibit T  cell function (31, 32). Our data are consistent 
with these findings, as we found a significant correlation between 
the relative Bregs and VL in our viremic patients. The treatment 
intensification patients had significantly lower Breg frequencies 
than the CO and PR patients but levels similar to those of the 
HC group and 3ART-treated subjects. Breg frequencies were 
already elevated in early HIV infection and may contribute to 
establishing a viral set point, as well as to disease progression 
(32). Thus, with an early start of ART, keeping Breg frequencies 
in a normal range, especially for patients with acute infection, 
might be a benefit from this treatment strategy. However, since 
Breg levels between the NE and 3ART patients were comparable, 
it is debatable if treatment intensification represents an advantage 
over conventional ART.
In HIV infection, Tregs are the most described and well-known 
cells with immunosuppressive capabilities. The ambiguous role 
of Tregs is discussed in several publications (18, 21–23, 44). Cao 
et al. argued, in reliance to their results, that Tregs have a role 
rather in disease progression than in hindering immune activa-
tion. They described elevated relative frequencies with disease 
progression (44). Indeed, we observed similar results. The rela-
tive Treg frequencies in the HC and CO groups were comparable 
(p =  0.34) and were significantly lower than those in PR and 
3ART patients (p < 0.009). Surprisingly, the lowest relative Treg 
frequencies were found in the NE patients with comparable 
levels in PHI and CHI. The difference between the NE patients 
and 3ART patients was especially remarkable (p <  0.0001), as 
the levels for those two groups were rather similar for all other 
cell types. Therefore, treatment intensification seems to have a 
beneficial effect for this specific cell type. Another reason for 
this finding could be the inclusion of maraviroc to intensify the 
treatment in the NE patients. Two studies analyzed the influence 
of maraviroc on Treg frequencies with contrary results (45, 46). 
While one study found a decrease in the relative Treg levels in 
maraviroc-treated individuals compared with maraviroc-free 
regimens (45), the other trial concluded that the reduction in 
viremia was the only reason for the Treg decline (46). While all 
the NE patients received maraviroc as part of their ART, there 
was only one individual in the 3ART group in our study with a 
maraviroc containing regimen. This patient had indeed a Treg 
frequency that was lower than the 3ART median and among the 
lowest values measured in this group. A third reason for the low 
Treg levels might be the intensified treatment itself, with lower 
levels of proviral DNA (especially in PHI) than usually measured 
in ART-treated patients. In the NE patients, we not only found 
low Treg frequencies but the absolute Treg numbers correlated 
well with the CD4 cell counts. This also reflected the healthy Treg 
compartment in this subgroup.
There was not a significant difference in any of the studied 
cell types between the PHI and CHI subgroups of the treatment 
intensification patients, which was surprising to us. We might have 
found a difference if our study groups had been larger as the highest 
values were always found in the group of CHI (with the exception 
of PMN-MDSCs). However, this finding, as it stands, questions the 
necessity for treatment start in acute HIV infection with regard to 
immune suppressive cells. On the other hand, the CHI patients in 
the NE study were chosen very selectively. The patients had to be 
virologically suppressed by a PI-based ART for at least 3 years and 
without a history of virological failure or blip (2, 3). It is possible 
that our findings emphasize this special selection, which is also 
reflected in the CD8 T cell response, and those patients would have 
had a benign disease course no matter which treatment.
In our study, we evaluated the CD8 T  cell responses on an 
epitope level to assess possible correlations between the suppres-
sive cells and the breadth of these responses. A limiting factor 
for this analysis is that the NE patients were treated for several 
years, and it is known that CD8 T  cell responses decline both 
in breadth and magnitude after the start of ART with the disap-
pearance of viremia (47). We restricted our analyses toward Gag 
and Nef, which are two of the most recognized HIV-1 proteins 
by CD8 T cells (39, 48, 49). Therefore, the results are limited to 
this part of the HIV genome. In our analyses, we did not find 
any correlations between the levels of the immune inhibitory 
cells and the CD8 T cell responses. A broad and strong immune 
response does not necessarily result in control of viral replication 
(39). In fact, EC control the HI virus below the detection limit 
but show less breadth and magnitude of immune response than 
PR (50) and preferentially target the HIV protein Gag (41, 51). 
In contrast to the similar frequencies of the analyzed cell subsets 
in the PHI and CHI subgroups, we found a significant difference 
between these groups in the breadth of the immune response. 
CHI had a broader CD8 T cell response despite the fact that PHI 
had higher CD4 counts than CHI. This outcome is in agreement 
with data from Altfeld et al. (52) and Addo et al. (39), showing 
that treatment in early infection results in an immune response 
that is narrower because the CD8 T cells were exposed to an HIV 
antigen for a shorter period of time. Consistently, all the HIV-1 
proteins analyzed were less recognized in the PHI subgroup than 
in the CHI subgroup.
Gag p17 and p15 contain more variable regions and, therefore, 
are often less recognized in HIV-infected individuals (39, 49, 53). 
The CO group had more responses toward these protein subunits 
than the other groups. Most interestingly, we also found strong 
responses toward Gag p17 and p15 in the CHI group; these 
responses were higher than those in the PR and 3ART groups. 
Assuming that the CO subjects benefit from responses toward 
Gag p17 and p15, this again stresses the specially selected patients 
of the CHI group.
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With this study, we comprehensively described several immu-
nosuppressive cell subsets in a unique patient population. How-
ever, there were some limitations. First, the correlations might 
not have reached significance because of the small group sizes. 
The NE study was a multi-center study with a necessity for 
overnight shipment of samples for some centers. Because of the 
fragile nature of MDSCs (54–56), we were only able to include 
patients from Munich in the MDSC analyses. This did not apply 
to the same degree for the Bregs and Tregs. Therefore, the groups 
for those assays were slightly larger. Second, we determined the 
immunosuppressive cells in the peripheral blood. Tregs are found 
to be underrepresented in this compartment (21), because the 
cells traffic to the tissues and lymph nodes. To the best of our 
knowledge, there are no data on humans for the other cells, at 
present, about other compartments than blood. Thus, future 
studies might provide insights if these cells act directly on CD8 
T cells in the lymphoid tissue.
Among the investigators of the study, it was highly discussed 
whether to stop treatment in this study population or not. In 
addition, if the treatment was stopped, should this be done with 
an additional intervention (e.g., vaccine or drug) or without. We 
think that it would be particularly interesting to stop treatment 
in the CHI group because, according to our results, the patients 
of this group seem very special as described earlier.
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